Published in Oncogene on September 10, 2001
Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood (2015) 1.39
Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J Exp Med (2004) 1.31
Role of Dok-1 and Dok-2 in leukemia suppression. J Exp Med (2004) 1.23
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics. Proc Natl Acad Sci U S A (2007) 1.10
Age-related defects in B lymphopoiesis underlie the myeloid dominance of adult leukemia. Blood (2007) 1.01
Mouse models as tools to understand and study BCR-ABL1 diseases. Am J Blood Res (2011) 0.88
CCN3: a key growth regulator in Chronic Myeloid Leukaemia. J Cell Commun Signal (2009) 0.85
Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia. Cell Rep (2013) 0.80
Targeted therapy of chronic myeloid leukemia. Biochem Pharmacol (2010) 0.80
The molecular basis of myeloid malignancies. Proc Jpn Acad Ser B Phys Biol Sci (2014) 0.78
Novel working hypothesis for pathogenesis of hematological malignancies: combination of mutations-induced cellular phenotypes determines the disease (cMIP-DD). J Biochem (2015) 0.76
Mechanisms determining the fate of hematopoietic stem cells. Stem Cell Investig (2015) 0.76
Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia. Mol Cell Oncol (2014) 0.75
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia (2017) 0.75
Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature (1980) 6.76
Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci U S A (1978) 6.38
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell (1980) 5.68
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 5.20
An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell (1984) 4.78
Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci U S A (1988) 4.40
BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol (1991) 4.31
Relationship of retrovirus polyprotein cleavages to virion maturation studied with temperature-sensitive murine leukemia virus mutants. J Virol (1978) 4.06
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
Long-term culture of B lymphocytes and their precursors from murine bone marrow. Proc Natl Acad Sci U S A (1982) 3.74
Differential expression of myc family genes during murine development. Nature (1986) 3.57
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (1986) 3.53
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50. J Virol (1980) 3.30
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A (1987) 3.03
Cellular maturation of oncornavirus glycoproteins: topological arrangement of precursor and product forms in cellular membranes. Virology (1977) 3.01
Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol (1985) 2.91
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol (1989) 2.87
A normal cell protein cross-reactive to the major Abelson murine leukaemia virus gene product. Nature (1979) 2.85
Lethal effect of the Abelson murine leukemia virus transforming gene product. Cell (1981) 2.82
Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med (1994) 2.75
Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science (1996) 2.71
Dominant negative MYC blocks transformation by ABL oncogenes. Cell (1992) 2.64
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Retracted Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science (2001) 2.52
Structure of the murine leukemia virus envelope glycoprotein precursor. J Virol (1979) 2.51
Preparation of syngeneic tumor regressor serum reactive with the unique determinants of the Abelson murine leukemia virus-encoded P120 protein at the cell surface. J Virol (1979) 2.50
Leukemia and the disruption of normal hematopoiesis. Cell (1991) 2.43
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J (1998) 2.36
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A (1990) 2.36
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell (1991) 2.29
A single bone marrow-derived stromal cell type supports the in vitro growth of early lymphoid and myeloid cells. Cell (1987) 2.27
Structural characteristics of some murine RNA tumor viruses studied by lactoperoxidase iodination. Proc Natl Acad Sci U S A (1973) 2.18
A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci U S A (1980) 2.16
Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule. J Virol (1980) 2.16
The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res (1988) 2.10
Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity (1996) 2.07
The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell (1991) 2.06
Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase. Proc Natl Acad Sci U S A (1994) 2.04
The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am (1999) 2.00
Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med (1998) 1.99
Murine B cell lymphopoiesis in long term culture. J Immunol Methods (1984) 1.98
Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A (1986) 1.97
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science (1987) 1.94
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci U S A (1985) 1.94
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol (1996) 1.93
Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity. J Virol (1984) 1.93
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties. Mol Cell Biol (1985) 1.92
Vesicular stomatitis virus glycoprotein is necessary for H-2-restricted lysis of infected cells by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A (1978) 1.88
Abelson murine leukemia virus mutants deficient in kinase activity and lymphoid cell transformation. J Virol (1980) 1.85
Phosphatidylinositol 3-kinase-gamma activates Bruton's tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci U S A (1997) 1.85
Temporal differences in the activation of three classes of non-transmembrane protein tyrosine kinases following B-cell antigen receptor surface engagement. Proc Natl Acad Sci U S A (1994) 1.83
Abelson virus-infected cells can exhibit restricted in vitro growth and low oncogenic potential. J Virol (1981) 1.80
Mechanism of formation of pseudotypes between vesicular stomatitis virus and murine leukemia virus. Cell (1977) 1.80
Impaired expansion of mouse B cell progenitors lacking Btk. Immunity (1995) 1.79
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science (1987) 1.76
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells. J Virol (1981) 1.73
Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell (1995) 1.73
The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev (2000) 1.71
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol (1989) 1.67
Regulation of Btk by Src family tyrosine kinases. Mol Cell Biol (1996) 1.66
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A (2001) 1.65
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro. Science (1992) 1.62
Polypeptides of Moloney sarcoma-leukemia virions: their resolution and incorporation into extracellular virions. Virology (1974) 1.61
Xid-like phenotypes: a B cell signalosome takes shape. Immunity (2000) 1.60
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science (1988) 1.59
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J Exp Med (1995) 1.59
Transformation of immature lymphoid cells by Abelson murine leukemia virus. Immunol Rev (1979) 1.58
Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity (2001) 1.58
A GDP dissociation inhibitor that serves as a GTPase inhibitor for the Ras-like protein CDC42Hs. Science (1992) 1.58
Activation of Bruton's tyrosine kinase (BTK) by a point mutation in its pleckstrin homology (PH) domain. Immunity (1995) 1.56
Tyrosine phosphorylation and activation of Bruton tyrosine kinase upon Fc epsilon RI cross-linking. Mol Cell Biol (1994) 1.54
Redundant and opposing functions of two tyrosine kinases, Btk and Lyn, in mast cell activation. J Immunol (2000) 1.54
Differential complementation of Bcr-Abl point mutants with c-Myc. Science (1994) 1.52
Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes. Mol Cell Biol (1983) 1.48
Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A (1991) 1.46
Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci U S A (1997) 1.42
Association and activation of Btk and Tec tyrosine kinases by gp130, a signal transducer of the interleukin-6 family of cytokines. Blood (1995) 1.42
Synergism of v-myc and v-Ha-ras in the in vitro neoplastic progression of murine lymphoid cells. Mol Cell Biol (1986) 1.42
Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res (1998) 1.41
Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet (1990) 1.40
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci U S A (2004) 1.39
In vivo tyrosine phosphorylations of the Abelson virus transforming protein are absent in its normal cellular homolog. Cell (1982) 1.39
Btk function in B cell development and response. Semin Immunol (1998) 1.38
SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence. Mol Cell Biol (1993) 1.38
Role of Bruton's tyrosine kinase in immunodeficiency. Curr Opin Immunol (1994) 1.37
Long-term culture of murine bone marrow precursors of B lymphocytes. Methods Enzymol (1987) 1.37
Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene (1998) 1.37
Differentiation of cloned populations of immature B cells after transformation with Abelson murine leukemia virus. Cell (1983) 1.36
A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction. Mol Cell Biol (1992) 1.35
The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain. J Biol Chem (1996) 1.34
Site-directed deletions of Abelson murine leukemia virus define 3' sequences essential for transformation and lethality. J Virol (1983) 1.33
A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. BMC Immunol (2001) 1.29
Retracted Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4. J Biol Chem (2001) 1.26
Monoclonal antibody to the amino-terminal L sequence of murine leukemia virus glycosylated gag polyproteins demonstrates their unusual orientation in the cell membrane. J Virol (1986) 1.22
The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function. Semin Immunol (1995) 1.22
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci U S A (1993) 1.22
Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules. J Virol (1986) 1.21
Oncornavirus budding: kinetics of formation and utilization of viral membrane glycoprotein. Virology (1976) 1.21